GlassScriptPhysician profile
Ghazwan A Atto
NPI 1578553301
$20,558.30
in general payments reported to CMS, 2019-2025
84 companies · $2,938 in 2025
The $2,938 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,844 · 2020: $2,121 · 2021: $3,430 · 2022: $3,010 · 2023: $3,541 · 2024: $2,674 · 2025: $2,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,136 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,135.81 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,906.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,479.31 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,343.43 | 2019-2025 | Vraylar, Linzess, Qulipta |
| Lilly USA, LLC | $1,276.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,166.69 | 2019-2025 | Otezla, Repatha, Enbrel |
| Pfizer INC. | $1,041.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $928.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $796.99 | 2019-2024 | Ofev, Stiolto Respimat, Jardiance |
| Merck Sharp & Dohme LLC | $741.86 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Janssen Pharmaceuticals, INC | $648.89 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $509.11 | 2019-2024 | |
| Astellas Pharma US INC | $491.97 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $480.13 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $468.74 | 2019-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $457.24 | 2019-2024 |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.64 | 2019-2025 | Xifaxan |
| Merz North America, INC. | $418.12 | 2023 | Xeomin |
| Allergan, INC. | $366.33 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $361.37 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $339.60 | 2022-2025 | Rexulti |
| Corcept Therapeutics | $337.57 | 2020-2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $320.68 | 2020-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $315.92 | 2023-2025 | Sunosi, Auvelity, Symbravo |
| Xeris Pharmaceuticals, INC. | $293.79 | 2022-2025 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $258.16 | 2019-2022 | |
| Amarin Pharma, INC. | $235.19 | 2019-2022 | |
| Medtronic, INC. | $225.74 | 2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Sumitomo Pharma America, INC. | $192.49 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.65 | 2024-2025 | Caplyta |
| Corium, LLC | $153.44 | 2023 | Adlarity |
| Ucb, INC. | $141.34 | 2019-2025 | Nayzilam |
| Biogen, INC. | $128.42 | 2021-2022 | |
| Mylan Specialty L.P. | $121.28 | 2019-2021 | |
| Radius Health, INC. | $108.82 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $92.48 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $90.92 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $85.46 | 2020-2021 | |
| Eisai INC. | $84.61 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $71.27 | 2021-2024 | Ingrezza |
| Horizon Therapeutics Plc | $68.97 | 2020-2023 | Krystexxa |
| Dexcom, INC. | $68.75 | 2022-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $65.71 | 2021-2024 | Watchman Flx |
| Lundbeck LLC | $64.39 | 2021-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $62.45 | 2025 | Zenpep, Vowst |
| Ultragenyx Pharmaceutical INC. | $62.16 | 2020-2021 | |
| United Therapeutics Corporation | $54.76 | 2025 | Tyvaso |
| Seqirus USA INC | $51.57 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Grifols USA, LLC | $51.34 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $49.36 | 2023-2024 | Inpefa |
| Genentech USA, INC. | $45.52 | 2019-2021 | |
| Inari Medical, INC. | $42.23 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Jazz Pharmaceuticals INC. | $41.87 | 2020-2021 | |
| Esperion Therapeutics, INC. | $41.32 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $41.10 | 2019 | |
| Abbott Laboratories | $39.00 | 2022-2024 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $38.45 | 2023 | |
| Krystal Biotech INC | $37.38 | 2025 | Vyjuvek |
| Ibsa Pharma INC. | $34.95 | 2020-2022 | |
| Insulet Corporation | $34.64 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $33.63 | 2024-2025 | Amvuttra, Givlaari |
| Impulse Dynamics (USA) INC. | $28.36 | 2023 | Optimizer |
| Mannkind Corporation | $28.05 | 2019 | |
| Phathom Pharmaceuticals, INC. | $26.07 | 2024-2025 | Voquezna |
| Avanir Pharmaceuticals, INC. | $22.05 | 2019 | |
| Sage Therapeutics, LLC | $21.03 | 2025 | Zurzuvae |
| Genzyme Corporation | $20.35 | 2024 | |
| Exact Sciences Corporation | $19.13 | 2024 | Cologuard Collection Kit |
| Cmp Pharma, INC. | $18.78 | 2022 | |
| Upsher-Smith Laboratories LLC | $18.62 | 2020 | |
| Alkermes, INC. | $17.68 | 2025 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $17.66 | 2023 | Belbuca |
| Gilead Sciences, INC. | $17.60 | 2021 | |
| Shield Therapeutics INC | $17.55 | 2022 | |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Ferring Pharmaceuticals INC. | $16.95 | 2023 | Rebyota |
| Tactile Systems Technology INC | $15.79 | 2021 | |
| Sanofi Pasteur INC. | $15.27 | 2023 | |
| Antares Pharma, INC. | $15.21 | 2025 | Xyosted |
| Mimedx Group, INC. | $13.98 | 2025 | |
| Cequr Corporation | $13.66 | 2024 | Cequr Simplicity |
| Abiomed | $13.36 | 2023 | Impella |
| Supernus Pharmaceuticals, INC. | $13.07 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.45 | 2019 | |
| Currax Pharmaceuticals LLC | $3.50 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$18,959.20 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghazwan Atto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.